I'm LongbridgeAI, I can summarize articles.Moleculin Biotech reported promising preliminary data from its MIRACLE trial, showing a 24% complete remission rate for Annamycin plus cytarabine in relapsed/refractory AML patients. Results were particularly strong for venetoclax-failure patients and showed no cardiotoxicity. Enrollment is nearing completion, with final unblinded data expected early 2027. While analysts maintain a Buy rating, AI analysis rates the stock Neutral due to weak financials and bearish technicals.
Moleculin Biotech ( (MBRX) ) has shared an announcement.
On July 31, 2026, Moleculin reported updated preliminary blinded data from Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine (AnnAraC) in relapsed or refractory AML, showing a complete remission rate of 24% and composite complete remission of 37% among 62 evaluable patients. Notably, patients who had previously failed venetoclax-based therapy achieved similar blinded CR and CRc rates of 23% and 37%, roughly three times published salvage remission benchmarks, while the trial continues to show no evidence of cardiotoxicity.
Enrollment for Part A had reached 74 of 90 subjects as of July 31, 2026, with final treatment of the 90th patient expected in September and comprehensive unblinded data anticipated between December 2026 and February 2027. The earlier June 2026 interim unblinding of 45 patients showed higher remission rates in both Annamycin arms versus control after a single treatment cycle, and management indicated these upcoming readouts could be pivotal for validating Annamycin’s profile, advancing the trial into Part B, strengthening the regulatory pathway, and expanding partnering prospects for shareholders.
The most recent analyst rating on (MBRX) stock is a Buy
with a $10.00 price target.
To see the full list of analyst forecasts on Moleculin Biotech stock,
see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
The score is held down primarily by very weak financial performance (no revenue, sizable ongoing losses, and sustained negative free cash flow) and a strong bearish technical backdrop (price far below all key moving averages). Valuation provides little support because the negative P/E reflects loss-making operations and no dividend yield is available.
To see Spark’s full report on MBRX stock,
click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage oncology company developing novel therapeutics for acute myeloid leukemia and other cancers, with a focus on its anthracycline candidate Annamycin. The company is targeting difficult-to-treat, relapsed or refractory AML patients, including those who have failed frontline venetoclax-based regimens, through its global MIRACLE Phase 2/3 trial.
Average Trading Volume: 552,456
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.26M
For an in-depth examination of MBRX stock, go to TipRanks’ Overview page.